Hjem
Kjell-Morten Myhrs bilde

Kjell-Morten Myhr

Instituttleder
  • E-postKjell-Morten.Myhr@uib.no
  • Telefon+47 55 97 60 31+47 414 47 868
  • Besøksadresse
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2016. Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. Multiple Sclerosis. 104-111.
  • 2015. Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 21-28.
  • 2015. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis. 1856-1864.
  • 2015. The EnvIMS study: Design and methodology of an international case-control study of environmental risk factors in multiple sclerosis. Neuroepidemiology. 173-181.
  • 2015. Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study. Journal of Neurology. 1271-1277.
  • 2015. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
  • 2015. Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
  • 2015. Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. European Journal of Human Genetics. 688-692.
  • 2015. Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. European Journal of Neurology. 328-333.
  • 2015. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain. 632-643.
  • 2015. Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
  • 2015. Cerebrospinal fluid proteomics in multiple sclerosis. Biochimica et Biophysica Acta - Proteins and Proteomics. 746-756.
  • 2015. Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Multiple Sclerosis. 388-395.
  • 2014. Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Multiple Sclerosis. 669-674.
  • 2014. Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. Journal of Neuroimmunology. 174-179.
  • 2014. Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 141-144.
  • 2014. Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology. 60-65.
  • 2014. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. Multiple Sclerosis. 1074-1080.
  • 2014. Health related quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurologica Scandinavica. 21-26.
  • 2014. Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
  • 2014. Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
  • 2014. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry. 1109-1115.
  • 2014. Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis. 1833-1840.
  • 2013. Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. Journal of Neurology. 1481-1488.
  • 2013. Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Multiple Sclerosis. 451-457.
  • 2013. Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLOS ONE. 9 sider.
  • 2013. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Annals of Neurology. 430-432.
  • 2013. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. American Journal of Human Genetics. 854-865.
  • 2013. Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Multiple Sclerosis. 1028-1034.
  • 2013. Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLOS ONE. 9 sider.
  • 2013. Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica. 16-23.
  • 2013. Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No. Multiple Sclerosis. 1692-1693.
  • 2013. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis. 1074-1083.
  • 2013. Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
  • 2013. Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. PLOS ONE. 5 sider.
  • 2013. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis. 1533-1538.
  • 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics. 1353-1360.
  • 2013. Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLOS ONE. 5 sider.
  • 2013. A ‘‘candidate-interactome’’ aggregate analysis of genome-wide association data in multiple sclerosis. PLOS ONE.
  • 2012. ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. Archives of Neurology. 1044-1051.
  • 2012. Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurologica Scandinavica. 63-69.
  • 2012. Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 267-273.
  • 2012. The cuprizone model: regional heterogeneity of pathology. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 648-657.
  • 2012. The cost of multiple sclerosis in Norway. European Journal of Health Economics. 81-91.
  • 2012. The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 20-23.
  • 2012. Poor Sleep in Patients with Multiple Sclerosis. PLOS ONE. 5 sider.
  • 2012. Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course. Journal of Neuroimmunology. 107-110.
  • 2012. Month of birth as a risk factor for multiple sclerosis: an update. Acta Neurologica Scandinavica. 58-62.
  • 2012. Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients. Neuroepidemiology. 84-93.
  • 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 1116-1124.
  • 2012. Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Acta Neurologica Scandinavica, Supplementum. 84-89.
  • 2012. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurologica Scandinavica. 90-96.
  • 2012. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. Acta Neurologica Scandinavica. 24-30.
  • 2012. A need for national registries and international collaborative research in multiple sclerosis. Acta Neurologica Scandinavica. 1-3.
  • 2011. The influence of warm versus cold climate on the effect of physiotherapy in multiple sclerosis. Acta Neurologica Scandinavica. 45-52.
  • 2011. Risk of MS is not associated with exposure to crude oil, but increases with low level of education. Multiple Sclerosis. 780-787.
  • 2011. Prevalence and incidence of multiple sclerosis in Oppland County – a cross-sectional population-based study in a landlocked county of Eastern Norway. Acta Neurologica Scandinavica. 250-257.
  • 2011. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis. 1074-1078.
  • 2011. How long can you keep working with benign multiple sclerosis? Journal of Neurology, Neurosurgery and Psychiatry. 78-82.
  • 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 214-219.
  • 2011. Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance. European Journal of Neurology. 114-120.
  • 2011. Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus. Genes and Immunity. 191-198.
  • 2011. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLOS ONE. 8 sider.
  • 2011. Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. European Journal of Human Genetics. 1100-1103.
  • 2010. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
  • 2010. The influence of warm versus cold climate on the effect of physiotherapy in multiple sclerosis. Acta Neurologica Scandinavica. 45-52.
  • 2010. Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29). Acta Neurologica Scandinavica. 244-251.
  • 2010. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurology. 4 sider.
  • 2010. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. In Vivo. 185-188.
  • 2010. Norwegian Sami differs significantly from other Norwegians according to their HLA profile. Tissue Antigens. 207-217.
  • 2010. Coping with multiple sclerosis: a 5-year follow-up study. Acta Neurologica Scandinavica. 336-342.
  • 2010. Benign multiple sclerosis: a need for a consensus. Acta Neurologica Scandinavica. 44-50.
  • 2010. Association to the Glypican-5 gene in multiple sclerosis. Journal of Neuroimmunology. 194-197.
  • 2010. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. European Journal of Human Genetics. 502-504.
  • 2010. A multivariate approach to reveal biomarker signatures for disease classification: application to mass spectral profiles of cerebrospinal fluid from patients with multiple sclerosis. Journal of Proteome Research. 3608-3620.
  • 2009. Vitamin D treatment in multiple sclerosis. Journal of the Neurological Sciences. 104-108.
  • 2009. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology. 519-529.
  • 2009. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology. 519-529.
  • 2009. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Multiple Sclerosis. 942-950.
  • 2009. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Experimental Neurology. 160-166.
  • 2009. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. The Lancet. 1503-1511.
  • 2009. Discriminating Variable Test and Selectivity Ratio Plot: Quantitative Tools for Interpretation and Variable (Biomarker) Selection in Complex Spectral or Chromatographic Profiles. Analytical Chemistry. 2581-2590.
  • 2009. Depressive symptoms and coping in newly diagnosed patients with multiple sclerosis. Multiple Sclerosis. 638-643.
  • 2009. Biomarker discovery in mass spectral profiles by means of selectivity ratio plot. Chemometrics and Intelligent Laboratory Systems. 35-48.
  • 2009. Antibodies against interferon-beta in multiple sclerosis. Journal of Neuroimmunology. 148-150.
  • 2009. A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. Clinical Nutrition. 83-87.
  • 2009. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes and Immunity. 120-124.
  • 2008. mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis. PLOS ONE. 1-7.
  • 2008. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Archives of Neurology. 809-811.
  • 2008. The cuprizone model for demyelination. Acta Neurologica Scandinavica. 72-76.
  • 2008. The SH2D2A gene and susceptibility to multiple sclerosis. Journal of Neuroimmunology. 152-158.
  • 2008. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Multiple Sclerosis. 1191-1198.
  • 2008. Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. Multiple Sclerosis. 1084-1090.
  • 2008. Quality of life among young patients with ischaemic stroke compared with patients with multiple sclerosis. Acta Neurologica Scandinavica. 181-185.
  • 2008. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. Journal of Neurology. 623-627.
  • 2008. Diagnosis and treatment of multiple sclerosis. Acta Neurologica Scandinavica. 12-21.
  • 2008. Depression and anxiety amongst multiple sclerosis patients. European Journal of Neurology. 239-245.
  • 2008. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes and Immunity.
  • 2007. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Multiple Sclerosis. 106-112.
  • 2007. Pretreatment of mass spectral profiles: Application to proteomic data. Analytical Chemistry. 7014-7026.
  • 2007. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. PROTEOMICS - Clinical Applications. 699-711.
  • 2007. Patient information and coping styles in multiple sclerosis. Multiple Sclerosis. 792-799.
  • 2007. Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami. Tissue Antigens. 299-304.
  • 2007. Is smoking an extra hazard in pregnant MS women? Findings from a population-based registry in Norway. European Journal of Neurology. 1113-1117.
  • 2007. Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurologica Scandinavica. 46-50.
  • 2007. Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis. 386-392.
  • 2007. Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis. 386-392.
  • 2007. Fc gamma receptor polymorphisms are not associated with autoimmune Addison's disease. Scandinavian Journal of Immunology. 555-558.
  • 2007. Familial effects on the clinical course of multiple sclerosis. Neurology. 376-383.
  • 2007. Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. Journal of Neurology, Neurosurgery and Psychiatry. 1097-1102.
  • 2007. A follow-up study of Nordic multiple sclerosis candidate gene regions. Multiple Sclerosis. 584-589.
  • 2006. The Norwegian Multiple Sclerosis National Competence Centre and National Multiple Sclerosis Registry - a resource for clinical practice and research. Acta Neurologica Scandinavica. 37-40.
  • 2006. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurologica Scandinavica. 51-54.
  • 2006. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurologica Scandinavica. 51-54.
  • 2006. Multippel sklerose. Norsk tidsskrift for logopedi. 5-9.
  • 2006. Multiplexed phosphoprotein analysis in immune cells. Acta Neurologica Scandinavica. 58-60.
  • 2006. Health-related quality of life among young adults with ischemic stroke on long-term follow-up. Stroke. 1232-2336.
  • 2006. Fc gamma R and multiple sclerosis: an overview. Acta Neurologica Scandinavica. 61-63.
  • 2006. Benign multiple sclerosis. Acta Neurologica Scandinavica. 55-57.
  • 2006. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology. 182-186.
  • 2005. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 1961-1963.
  • 2005. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatrica Scandinavica. 463-468.
  • 2005. Mild depression in young adults with cerebral infarction at long-term follow-up: A population-based study. European Journal of Neurology. 194-198.
  • 2005. Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients. Journal of Neuroimmunology. 5 sider.
  • 2005. High dose methylprednisolone induces FcgammaR1 on granulocytes in MS-patients. Journal of Neuroimmunology. 138-142.
  • 2005. Fc gamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis. 277-282.
  • 2005. Fatigue at long-term follow-up in young adults with cerebral infarction. Cerebrovascular Diseases. 245-250.
  • 2005. Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. Scandinavian Journal of Immunology. 71-74.
  • 2005. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology. 416-421.
  • 2005. Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology. 416-421.
  • 2005. Ethnic Variations of IL-10 Polymorphisms in a Sami and Norwegian Population. Scandinavian Journal of Immunology. 71-74.
  • 2005. Do all young ischemic stroke patients need long-term secondary preventive medication? Neurology. 609-611.
  • 2004. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 706-710.
  • 2004. Long-term outcome of cerebral infarction in young adults. Acta Neurologica Scandinavica. 107-112.
  • 2004. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens. 237-247.
  • 2004. Etiology of and risk factors for cerebral infarction in young adults in western Norway: a population-based case-control study. European Journal of Neurology. 25-30.
  • 2004. Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Multiple Sclerosis. 5-8.
Vitenskapelig foredrag
  • 2015. Vitamin D og interferon-behandling ved multippel sklerose.
  • 2015. Evidence of preclinical disease activity­ a prospective study on cognitive and physical performance prior to first symptom of multiple sclerosis.
  • 2014. Level of education and multiple sclerosis risk after adjustment for known risk factors: the EnvIMS study.
  • 2007. Target projection and proper data pre-treatment for the analysis of proteomic profiles.
  • 2007. Preteatment of Mass Spectral Profiles: Application to proteomic data.
  • 2007. Analysis of Proteomic Profiles.
  • 2006. Costs and quality of life in patients with multiple sclerosis in Norway compared to 9 other European countries.
  • 2000. Reduced quality of life among MS patients with sexual disturbance and bladder dysfunction.
  • 2000. Quality of life as a predictor for change in disability in multiple sclerosis.
  • 2000. Livskvalitet hos multippel sklerose pasienter - en utfordring for sykepleien.
  • 2000. Livskvalitet hos multippel sklerose pasienter.
  • 1999. The quality of life of multiple sclerosis patients in a treatment trial with recombinant interferon-alfa-2a.
  • 1999. Lack of agreement between objective disease measures and the Quality of Life in a treatment trial in multiple sclerosis.
  • 1999. Expanded Disability Status Scale scores and the Quality of Life of Multiple Sclerosis patients. An epidemiological study.
Sammendrag/abstract
  • 2017. alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. Multiple Sclerosis. 712-712.
  • 2017. Cancer risk in multiple sclerosis. Multiple Sclerosis. 486-487.
  • 2013. Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS. Multiple Sclerosis. 33-34.
  • 2013. Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. Multiple Sclerosis. 400-400.
  • 2012. WalkAide - A multidisciplinary model for adjustment and evaluation. Multiple Sclerosis. S30-S30.
  • 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • 2012. Poor sleep in patients with multiple sclerosis. European Journal of Neurology. 706-706.
  • 2012. Overweight as a risk factor for multiple sclerosis. European Journal of Neurology. 353-353.
  • 2012. Norwegian quality registry for biological drugs: the NOKBIL project. Scandinavian Journal of Rheumatology. 50-50.
  • 2012. An age at exposure effect between sun exposure and the risk of MS in Norway and Italy. Multiple Sclerosis. s15-s15.
  • 2011. VITAMIN D, LIFESTYLE FACTORS AND RISK OF MULTIPLE SCLEROSIS. European Journal of Neurology. 16-16.
  • 2011. The Risk of Multiple Sclerosis Among Petroleum Workers Exposed to Crude Oil and Other Hydrocarbons. Epidemiology. S60-S60.
  • 2010. Trend of association to the Glypican 5 gene region to multiple sclerosis. European Journal of Neurology. 221-221.
  • 2010. The definition of benign multiple sclerosis: a methodical approach. European Journal of Neurology. 494-494.
  • 2009. Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. Multiple Sclerosis. S5-S5.
  • 2009. International case control study on risk factors for multiple sclerosis (MS): pilot testing the questionnaire. Multiple Sclerosis. 1403-1403.
  • 2009. Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
  • 2009. Fatigue in multiple sclerosis is associated with self-perceived health, but less with physical performance. Multiple Sclerosis. S225-S225.
  • 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • 2008. Gait and balance improved in patients with multiple sclerosis after inpatient physiotherapy. Multiple Sclerosis. S152-S152.
  • 2008. Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. Multiple Sclerosis. S90-S91.
  • 2008. Early diagnosis and biomarker discovery from mass spectral profiles: application to multiple sclerosis. Multiple Sclerosis. S285-S285.
  • 2008. Biomarker discovery from mass spectral profiles: A combined proteomics and multivariate analysis. European Journal of Pharmaceutical Sciences. S27-S27.
  • 2008. An international case-control study of risk factors for multiple sclerosis. Multiple Sclerosis. S197-S197.
  • 2008. Acceptability and cross-cultural feasibility of it self-administered questionnaire on past exposure to putative environmental risk factors for multiple sclerosis. Multiple Sclerosis. S196-S196.
  • 2007. Smoking habits in pregnant MS women. European Journal of Neurology. 278-278.
  • 2007. Perinatal factors and later development of multiple sclerosis. Multiple Sclerosis. S91-S92.
  • 2007. Individualised physiotherapy improved fatigue score in patients with multiple sclerosis. Multiple Sclerosis. S127-S127.
  • 2007. Increasing prevalence of multiple sclerosis in the elderly in western Norway. Multiple Sclerosis. S96-S96.
  • 2006. The role of SH2D2A gene polymorphisms in multiple sclerosis. Multiple Sclerosis. S72-S72.
  • 2006. The role of SH2D2A gene polymorphisms in development of multiple sclerosis. Tissue Antigens. 528-529.
  • 2006. Pregnancy, delivery and birth outcome in mothers prior to debut of multiple sclerosis. European Journal of Neurology. 28-29.
  • 2006. Low prevalence of multiple sclerosis in a Sami population is related to low frequency of the disease-associated HLA DR15-DQ6 haplotype. Tissue Antigens. 523-523.
  • 2006. Low prevalence of multiple sclerosis and the HLA CR15-DQ6 halotype in Sami. Multiple Sclerosis. 71-71.
  • 2006. Health-related quality of life in secondary progressive multiple sclerosis. European Journal of Neurology. 27-27.
  • 2005. The CD28/CTLA4/ICOS gene region does not show assosiation in Norwegian multiple sclerosis patients. Genes and Immunity. 1 sider.
Vitenskapelig oversiktsartikkel/review
  • 2020. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. 1-10.
  • 2019. Neurofilament light chain as a biomarker in multiple sclerosis. 1-6.
  • 2019. B cell depletion in the treatment of multiple sclerosis. 261-271.
  • 2017. Progressive multifocal leukoencephalopathy. 10 sider.
  • 2015. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. 29-36.
  • 2015. The Norwegian Multiple Sclerosis Registry and Biobank. 24-28.
  • 2014. Multiple sclerosis registries in Europe - Results of a systematic survey. 1523-1532.
  • 2014. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. 1210-1216.
  • 2013. Neuromyelitis optica. 2057-2061.
  • 2013. Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. 24-30.
  • 2012. Polyunsaturated fatty acids in multiple sclerosis therapy. 70-75.
  • 2009. Corticosteroids in the treatment of multiple sclerosis. 73-80.
  • 2003. New diagnostic criteria in multiple sclerosis. 1345-1348.

Se fullstendig oversikt over publikasjoner i CRIStin.